Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine + Interferon for Post-Transplant Recurrence in Myeloid Tumors
NCT04078399Phase 2Unknown
- Sponsor
- Shanghai General Hospital
- Start
- Aug 2019
- Primary completion
- Aug 2022
- Modality
- Cytokines & Interferons, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of azacitidine and interferon alfa in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN) and 1 more, sponsored by Shanghai General Hospital. Primary endpoint: Treatment response rate at 6 months. Status: unknown.
02
Drugs
azacitidineinterferon alfa
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)myeloproliferative neoplasms (MPN)chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT04078399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04078399.